Flurbiprofen

Nonsteroidal Anti-inflammatory Drug — MUSCULO-SKELETAL SYSTEM

Key facts

Flurbiprofen is an ofp drug in the Nonsteroidal Anti-inflammatory Drug class catalogued in DrugCentral. It was first approved by the FDA in 1986. Its mechanism of action is classified as Cyclooxygenase Inhibitors. DrugCentral lists 11 molecular targets, including PTGS1, PTGS2 and Ptgs1. Recorded indications include Osteoarthritis, Prevention of Ocular Surgery-Induced Miosis and Rheumatoid arthritis.

• Approval status: ofp (first approved 1986 by the FDA).
• Drug class: Nonsteroidal Anti-inflammatory Drug.
• Mechanism of action: Cyclooxygenase Inhibitors.
• Molecular targets: PTGS1, PTGS2, Ptgs1 and Ptgs2 (11 listed in DrugCentral).
• Indications: Osteoarthritis, Prevention of Ocular Surgery-Induced Miosis and Rheumatoid arthritis.
• ATC code: M01AE09 (Propionic acid derivatives).
• Molecular formula: C15H13FO2; molecular weight 244.26 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Osteoarthritis
• Prevention of Ocular Surgery-Induced Miosis
• Rheumatoid arthritis

Off-label uses (1)

• Dysmenorrhea

Contraindications (20)

• Acute nephropathy
• Alcoholism
• Blood coagulation disorder
• Body fluid retention
• Cardiovascular event risk
• Chronic heart failure
• Coronary artery bypass graft
• Disease of liver
• Disorder of cardiovascular system
• Gastrointestinal hemorrhage
• Gastrointestinal perforation
• Gastrointestinal ulcer
• Hypertensive disorder
• Impaired wound healing
• Kidney disease
• Myocardial infarction
• Ocular Bleeding
• Peptic ulcer
• Pregnancy, function
• Smokes tobacco daily

Mechanism & targets

• Mechanism of action (MoA): Cyclooxygenase Inhibitors
• Established pharmacologic class: Nonsteroidal Anti-inflammatory Drug

Molecular targets (11)

Target	Gene	Action	Activity
Prostaglandin G/H synthase 1	PTGS1	inhibitor	IC50 8.74
Prostaglandin G/H synthase 2	PTGS2	inhibitor	IC50 8.39
Prostaglandin G/H synthase 1	Ptgs1	unknown	IC50 6.77
Prostaglandin G/H synthase 2	Ptgs2	unknown	IC50 6.30
Prostaglandin G/H synthase 1	PTGS1	unknown	Ki 6.00
Fatty acid-binding protein, liver	Fabp1	unknown	Ki 5.93
Aldo-keto reductase family 1 member C3	AKR1C3	unknown	IC50 5.81
Aldo-keto reductase family 1 member C1	AKR1C1	unknown	IC50 5.69
Aldo-keto reductase family 1 member C4	AKR1C4	unknown	IC50 5.53
Fatty acid-binding protein, intestinal	FABP2	unknown	Ki 4.59
Aldo-keto reductase family 1 member C2	AKR1C2	unknown	IC50 4.49

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1986-12-31	FDA	—	ALLERGAN

ATC classification

ATC code	Therapeutic hierarchy
M01AE09	MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS › Propionic acid derivatives
M02AA19	MUSCULO-SKELETAL SYSTEM › TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN › TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN › Antiinflammatory preparations, non-steroids for topical use
R02AX01	RESPIRATORY SYSTEM › THROAT PREPARATIONS › THROAT PREPARATIONS › Other throat preparations
S01BC04	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFLAMMATORY AGENTS › Antiinflammatory agents, non-steroids

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: CYP2C9 · Actionable PGx
• HCSC label: CYP2C9 · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Angioedema	202.9
Toxic anterior segment syndrome	151.6
Allergy test positive	93.8
Central pain syndrome	71.4
Urticaria	70.1
Drug reaction with eosinophilia and systemic symptoms	65.7
Eyelid oedema	57.3
Acute kidney injury	55.7
Ankylosing spondylitis	49.9
Lip oedema	48.3
Cross sensitivity reaction	45.0
Ischaemic cerebral infarction	43.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Flurbiprofen is on its molecule page.

• Molecular formula: C₁₅H₁₃FO₂
• Molecular weight: 244.26 g/mol
• CAS number: 5104-49-4
• InChIKey: SYTBZMRGLBWNTM-UHFFFAOYSA-N
• PubChem CID: 3394

CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Flurbiprofen used for?

DrugCentral lists the following indications for Flurbiprofen: Osteoarthritis, Prevention of Ocular Surgery-Induced Miosis and Rheumatoid arthritis.

How does Flurbiprofen work?

Flurbiprofen is classified as Cyclooxygenase Inhibitors; its molecular targets in DrugCentral include PTGS1 (inhibitor), PTGS2 (inhibitor), Ptgs1 and Ptgs2.

When was Flurbiprofen first approved?

Flurbiprofen was first approved by the FDA in 1986.

What drug class does Flurbiprofen belong to?

Flurbiprofen is in the Nonsteroidal Anti-inflammatory Drug class.

What is the chemical formula of Flurbiprofen?

Flurbiprofen has the molecular formula C15H13FO2 and a molecular weight of 244.26 g/mol.

Sources

• DrugCentral drug card 1219 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3989754 — compound record and bioactivity
• PubChem CID 3394 — chemical identifiers
• DrugBank DB00712 — drug record
• FDA UNII 5GRO578KLP — substance identity
• DailyMed: FDA labels for Flurbiprofen — current prescribing information (label search)
• UniProt P23219 (PTGS1) — target protein
• UniProt P35354 (PTGS2) — target protein
• UniProt P42330 (AKR1C3) — target protein
• UniProt Q04828 (AKR1C1) — target protein
• UniProt P17516 (AKR1C4) — target protein
• UniProt P12104 (FABP2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.